Checkpoint Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CKPT and other ETFs, options, and stocks.

About CKPT

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX.

CEO

James F. Oliviero

CEOJames F. Oliviero

Employees

Employees23

Headquarters

Waltham, Massachusetts

HeadquartersWaltham, Massachusetts

Founded

2014

Founded2014

Employees

Employees23

CKPT Key Statistics

Market cap

51.74M

Market cap51.74M

Price-Earnings ratio

-0.49

Price-Earnings ratio-0.49

Dividend yield

—

Dividend yield—

Average volume

422.07K

Average volume422.07K

High today

$1.48

High today$1.48

Low today

$1.42

Low today$1.42

Open price

$1.43

Open price$1.43

Volume

85.56K

Volume85.56K

52 Week high

$3.62

52 Week high$3.62

52 Week low

$1.30

52 Week low$1.30

Checkpoint Therapeutics

Why Robinhood?

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. Show more

CKPT Key Statistics

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX.